1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed) is sponsored by National Institutes of Health. Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed) is a forecasted funding opportunity on Grants.gov from National Institutes of Health. Fiscal Year: 2027. Assistance Listing Number(s): 93.279. <p style="margin-left:0px;">The National Institute on Drug Abuse (NIDA) seeks to advance its mission by establishing a Center that educates and supports researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics. The Center will also help advance the best concepts through initial experiments via technical and financial support. Previous NIDA-supported initiatives in early translational research have shown that drug addiction researchers are eager to acqui...
Application snapshot: target deadline rolling deadlines or periodic funding windows; published funding information See Grants.gov forecast notice for estimated funding details.; eligibility guidance Eligible applicant types: [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object].
Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
Get alerted about grants like this
Save a search for “National Institutes of Health” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicant types: [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object]. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Establishing a Center for the Advancement of SUD Pharmacotherapeutics (U54) is sponsored by National Institutes of Health (NIDA). Planning NOFO to establish a translational center for SUD pharmacotherapeutic development, training, and outreach. Application snapshot: target deadline March 10, 2026; published funding information Approximately $3,000,000 for first year, one award; eligibility guidance Governments, nonprofits, educational institutions, tribal organizations. Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
This non-competitive Notice of Funding Opportunity (NOFO) is intended to fund a single award to the current awardee institution of the Accelerating Medicines Partnership in Common Metabolic Diseases Knowledge Portal (AMP CMD KP), the Broad Institute, Inc. The AMP CMD program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time NOFO to provide funds to the AMP CMD KP to continue the development and maintenance of the web portal and underlying, curated knowledge base; which serves as the flagship resource encompassing the myriad types of data and information that provide an understanding of the biological heterogeneity in patients with CMDs and their related complications. In its next five-year period, the AMP CMD KP will be expected to continue its expansion of its datasets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base, and to develop a framework for independent sustainability. The application will be peer-reviewed and if it is not a meritorious application, it will not be funded. Funding Opportunity Number: RFA-DK-26-313. Assistance Listing: 93.847. Funding Instrument: CA. Category: HL. Award Amount: Up to $2M per award.